Spiriva® substitute

Circassia’s product is a particle-engineered formulation of the inhaled long-acting muscarinic antagonist tiotropium bromide delivered via dry powder inhaler (DPI).  The product targets direct substitution of Boehringer Ingelheim’s Spiriva® DPI, which is used in the treatment of chronic obstructive pulmonary disease.

Product progress

Circassia completed early technical work on the particle-engineered formulation of tiotropium bromide and progressed the product into development targeting an abbreviated regulatory route. We subsequently completed manufacture of stability batches of our formulation in preparation for a pharmacokinetic clinical study.

 

Pipeline status: Spiriva® substitute

ResearchPre-clinicalPhase IPhase IIPhase III /
Substitute
Approved

View Circassia's full pipeline chart